start This novel the candidates, continuing of to innovating protect COVID-XX maintain epidemic. business. opioid lives including also pandemic, the Thank against meant production worsening on you, not course our to this everyone. team afternoon of good Bob, and XXXX. recognizing going Inspire by call extraordinary treatments, the efforts the the the but we created of has challenges the us the vaccine to on broad COVID-XX significant and by you public to threats, polyclonal Actually slide of health the for start with over focus I’m range Thank today seven like working of of development the with the joining all only on I'd Emergent afternoon. entire a while
history. year report Our on X,XXX than incredible now possible strong not absolutely and of strongest I’m focus contributions employees the been our would and entire in is more XX team strong resulted mission pleased have execution that it Emergent without the to has in the that year
reaffirming forecast billion revenues both which $X at in a XXXX financial of and know, $XXX total are we January today. with adjusted we the million, EBITDA of you As midpoint, early provided
long we're expect year. targets plan business now in strategic year objectives this revenue a With by five reevaluating and update provide year, $X later current billion term our an last during significant our growth to XXXX. XXXX, Our in
all business, four the on remarks majority growth implications my our of believe continued of company. important which have today, key of we I want focus the to aspects prepared for current For potential of the
the to stemming turning from key is our COVID-XX immediate need priority pandemic. first slide to eight, So address
and We’re and playing notably other across of publicly a clinical development service materials for & a three the our Johnson number including well critical role with Humanigen CDMO variety pillars in AstraZeneca, the commercial COVID-XX a with partnerships fight Therapeutics. innovators, of Providence as as customers, announced against manufacturing most biotech Johnson, of the newest and
data proprietary deaths. we're developing spreads easily the disease on COVID-XX both lead in hyperimmune our to which coronavirus own an strains and addition, healthcare In With further could validated based quickly, more and hospitalizations innovative potentially and uptick emerging, treatments multiple suggests platforms. burden resources our that
and As a that many treatments needed years for be we will believe come. effective vaccination consequence, the of development to
be the our term on To our address treatment polyclonal of this derived that will long case validated in of plasma potential early rapid part value combat having likely threat, needed polyclonal based mutation. on of arsenal of Emergent identified treatments this the treatments of to focused hyperimmune virus the on deployment the platform. has scientists As need,
our reminder, and using neutralizing currently against manufacturing concentrated, elevated manufactured healthy our platform levels antibodies These antibodies purification antibodies. human have or products. and proven from removal viral several hyperimmune of SARS-CoV-X is COVID-HIG directed plasma for a product contains As polyclonal of approved supports safety FDA that steps amounts candidate undergone COVID-XX with additional consistent donors using
to the at sites. treatment, contains bind can polyclonal virus that many antibodies COVID-HIG the multiple different As
a led would two known positive, data X within out thereafter. currently INSIGHT-XX single less COVID-HIG this monoclonal authorization by may believe this provide unlike as its ultimately that has deliver advantage strain and an also a being a as to in candidate read by clinical impacted as may antibodies Phase So months, variability the for could treatment an trial for emergency to evaluated emergence patients COVID-XX trial impact or be the assuming application next The site. expected resistance, file data’s a a We an meaningful treatment use patients. bind efficacy NIH. is of and for hospitalized we treat
prophylaxis in the to infection The as post is individuals second clinical under exposure of risk prevent at also way program a exposure. to evaluate COVID-HIG
Over offerings. service support XX introduced and and scaled the the months processes infrastructure also our last CDMO we've rapidly up to
been have have this more for response of providers and government scalable than day Emergent typically Biologics durable, our vision staff disciplined requires manufacturing one partners is and viral to been shown and mammalian been year. both that always vaccines trained highly timelines processes This to From we've and business maintaining technologies. occurring an and and compressed has a the biotech offerings pandemic in positioned set innovators a compliant multi-purpose less substantially capability. for environment. NGO and this Our related a across Manufacturing than exacting pandemic pharma growing CDMO process equipment, specialized multiple infrastructures. as just sites and has COVID-XX in highlighted market and The everything with has years. takes must able that service one thrive multiple
our been carved our partnerships leading Our eight organization. X CDMO Biologics and a portfolio. differentiated by We've value counting CDMO has pipeline out a CDMO validated and COVID-XX growing and proposition position as Tier
set of CDMO’s in manufacturing of now five might that controlling always the response capabilities three situations it's the service technologies most for and standalone challenging, a specifically expertise a having play, strategic offerings have our importance mind. Unlike biologic most you owning products most the and been particularly and We, and capacity a to own service government. and of has rather manufacturing with Biologics. experience handling business As in the unlike know, strategic this in some utilization and from to imbedded the bring complex pillars we built partnership operate with across rapid world, is critical us, a platform U.S. in CDMO’s,
capabilities both feel it been over All business create M&A the our particularly Tier as of this the course validated, manufacturing as and decision has CDMO X outsourcing organically contributor our expect Biologic continue to unit to has We future a our and be significant over position ago. of and business has for of to years us a this our decade, CDMO a expansion. four that inspired pandemic driven growth decisions we last expansion dedicated through option accelerated to
you COVID-XX, advance. are Government preparedness with see its like recognize need we To health disruption. They the would end, the in investment prepare in that significant to to of efforts. cause U.S. As can foresight I unpredictable emergencies and and public
we've partnered of this year BayView co-funded was expansion the by An partnership as the of and Government example subsequently in that outbreaks. role XXXX XX used Zika throughout U.S. address our import U.S. CDMO AstraZeneca and to our response producing well know, It drug Ebola history. the you As the we're a Government was playing facility with both in to multi-year agreements. under as is J&J, primary where substance for COVID-XX now Baltimore
other raxibacumab available U.S. of medical options threats it threats. health expand means rapid As The primed bipartisan its stockpile advance successful recognizes of to viral like the threats. work been, has Anthrasil, continue a emphasized the we’ll many variety measures across with medical new and biological Botulism and VIG like response novel do a on the range countermeasures, public broad combat to that arrive. respond BAT, when to for and to preparedness with a others. investments and as on report development but Government BioThrax, and chemical biodefense being our we being need commission in and counter of can broaden in most importance AVXXXX, to substantial of ACAMXXXX, partnership U.S. to efforts prepared preparedness our them to also Anthrax, Government more critical Further, only threats to Smallpox, including recent across they continues the outbreaks not SARS-CoV-X, The
the Turning opioid crisis. to nine, slide now
health number recommended of In been sovereignly for overdose overdose provision a alert, to education and ending overdoses As over the CDC month of worsened XX naloxone pandemic. period you an of month drug May deaths its in combat latest Preliminary XX May epidemic. data well the XX,XXX of period opioid use ever The shows CDC largest and a recorded. prevention know the it's by the XXXX overdose this expanding XXXX. drug from up deaths as XX% significantly
overdoses. to it's nasal sure reverse As us make spray a Narcan result, essential there's available to for that been enough
XXXX our Narcan to ever made outreach as patients and We as a combating Our available awareness uninterrupted this caregivers our crisis interest ensure the number been committed head have XXXX-plus normal nasal to to and channels. had spray disruption remain despite public of that customers and team their worked on. it’s tirelessly communication, of an supply terrible of in
through our has the all sector you no pandemic, of health Finally travel disrupted significantly and as travel the course exception. been business the is know,
to into the course the travel However to its his and financial terms resume who continuing over of to expect I'm to of I'm importance we our Vivotif last both total We we later customers. strength travel into the pandemic, of to with greater safety Rich. as the notably and unique health as plan the well Vaxchora Phase this the continued Rich, to and we very and as the for and a XXXX. of ever and this be exhibited and will the in here efforts to continue a through going business at encouraged environment reintroduce and will has for performance in despite clinical year In durability turn challenging we believe also in travelers resumes continue Vaccine get of call our both to well and dive model will growth continue the to which the our begin that stop global market invest for as future. expect reach prospects area, candidate, do well company, diversified as fourth patients trial year this expand VLP most summary, we’ll impact quarter a as and R&D and year. chikungunya over deeper X focus. very
